Cough Hypersensitivity Syndrome Market Trends Report 2025 – For Business Development and Strategy Teams
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Cough Hypersensitivity Syndrome Market Growth in 2025?
The market size for cough hypersensitivity syndrome has witnessed robust growth recently. The market, which stood at $10.36 billion in 2024, is projected to rise to $11.03 billion in 2025, recording a compound annual growth rate (CAGR) of 6.4%. The significant growth during the historic period has been driven by factors such as heightened awareness, the measures taken in telemedicine and remote monitoring, public health initiatives, and funding for research.
What Is the Forecast for the Cough Hypersensitivity Syndrome Market Size Through 2029?
The market size of cough hypersensitivity syndrome is forecasted to witness robust expansion in the upcoming years, potentially reaching $14.65 billion by 2029 with a compound annual growth rate (CAGR) of 7.4%. This growth can be credited to universal health accessibility, persistent patient advocacy and support, as well as enhancements in quality of life. The forecast period is set to witness significant trends, including better diagnostic and screening resources, custom-tailored treatment methods, and the introduction of new medicines.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12989&type=smp
What are the Key Market Players in Cough Hypersensitivity Syndrome Market and How They’re Evolving?
Major companies operating in the cough hypersensitivity syndrome market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck and Co Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Wyeth Pharmaceuticals Inc., AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Mylan N.V., Lupin Limited, Cadila Pharmaceuticals, Almirall S.A., Akorn Operating Company LLC, Kudco Ireland Ltd., Prestige Consumer Healthcare Inc., GMP Laboratories of America Inc., The Betty Mills Company, Acura Pharmaceuticals Inc.
What Are the Primary Growth Drivers in the Cough Hypersensitivity Syndrome Market?
The escalating instances of chronic respiratory diseases are projected to be a driving force for the expansion of the cough hypersensitivity syndrome market in the future. These diseases encompass an array of enduring illnesses impacting the airways and lungs, leading to continual breathing difficulties and diminishing lung function over time. Therapies for cough hypersensitivity syndrome aim to ease discomfort, improve respiratory health, and thus, enhance the quality of life for patients afflicted with chronic respiratory conditions such as asthma. For instance, according to the Australian Institute of Health and Welfare in June 2023, approximately a third (30%) of Australians, totaling up to 7.5 million individuals, are grappling with chronic respiratory diseases. Furthermore, as per the data shared by the US-based National Center for Health Statistics (NCHS) in May 2024, the prevalence of asthma among adults 18 years and older in the United States saw an increase from 8.4% in 2021 to 8.7% in 2022. Also, the instances of asthma occurrences within the preceding twelve months rose from 3.3% in 2021 to 3.7% in 2022 for the same age group. Thus, the steep growth in instances of chronic respiratory diseases fuels the cough hypersensitivity syndrome market. The surge in the number of cigarette smokers is anticipated to drive the growth of the cough hypersensitivity syndrome market. Cigarette smokers, people who regularly smoke tobacco cigarettes, inhale smoke from burning tobacco leaves wrapped in paper. Cigarette smoking can cause cough hypersensitivity syndrome by irritating the airways, causing inflammation, and damaging the lung tissues. For instance, Statistics Canada reported in July 2022 that cigarette production saw a spike of 5.8% as compared to June 2021 and the total number of cigarettes sold also increased by 1.3%, touching 1.4 billion in June 2022. Furthermore, as per the Centers for Disease Control and Prevention in May 2023, around 28.3 million U.S. adults are smokers, and roughly 3.08 million middle and high school students in the U.S. use at least one tobacco product. Each day, about 1,600 U.S. youth under the age of 18 are smoking their first cigarette. Therefore, the rising demographic of cigarette smokers is predicted to drive the growth of the cough hypersensitivity syndrome market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12989&type=smp
What Are the Leading Segments in the Global Cough Hypersensitivity Syndrome Industry?
The cough hypersensitivity syndrome market covered in this report is segmented –
1) By Drug Class: Inhales Corticosteroids, Antitussive Agents, Short-acting Beta-2 Agonists, Anticholinergics, Proton Pump Inhibitors, Antihistamines, Other Drugs
2) By Route of Administration: Oral, Inhalation, Other Route Of Administration
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Inhaled Corticosteroids: Budesonide, Fluticasone, Beclomethasone
2) By Antitussive Agents: Dextromethorphan, Codeine, Benzonatate
3) By Short-acting Beta-2 Agonists: Albuterol, Levalbuterol
4) By Anticholinergics: Ipratropium Bromide, Tiotropium
5) By Proton Pump Inhibitors: Omeprazole, Esomeprazole, Lansoprazole
6) By Antihistamines: Cetirizine, Loratadine, Diphenhydramine
7) By Other Drugs: Mucolytics, Combination Therapy Drugs
What Are the Key Market Trends in the Cough Hypersensitivity Syndrome Industry?
Leading firms in the cough hypersensitivity syndrome market are dedicated to advancing asthma treatment options, such as asthma rescue inhalers, to improve patient results and overall quality of life. These rescue inhalers are compact devices that provide quick-acting medication to open airways swiftly. They can potentially alleviate sudden coughing bouts by temporarily decreasing airway sensitivity and offering relief from cough-related airway blockage. For instance, Teva Pharmaceutical Industries Ltd., a pharmaceutical company based in Israel, formed a partnership with Launch Therapeutics, a US clinical development corporation, in April 2024. The aim of this partnership is to expedite the clinical research program for their inhaler, the ICS-SABA (inhaled corticosteroid and short-acting beta-agonist), TEV-‘248. This inhaler blends fluticasone propionate and albuterol sulfate, and targets adult and pediatric asthma patients. The collaboration also hopes to minimize dependence on generic drugs.
Access The Full Report Here:
What Is the Regional Outlook for the Cough Hypersensitivity Syndrome Market?
North America was the largest region in the cough hypersensitivity syndrome market in 2024. The regions covered in cough hypersensitivity syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12989
This Report Delivers Insight On:
1. How big is the cough hypersensitivity syndrome market, and how is it changing globally?
2. Who are the major companies in the cough hypersensitivity syndrome market, and how are they performing?
3. What are the key opportunities and risks in the cough hypersensitivity syndrome market right now?
4. Which products or customer segments are growing the most in the cough hypersensitivity syndrome market?
5. What factors are helping or slowing down the growth of the cough hypersensitivity syndrome market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
